Elevated vascular endothelial growth factor levels in sera of patients with lung cancer

Nagio Takigawa, Yoshihiko Segawa, Nobukazu Fujimoto, Katsuyuki Hotta, Kenji Eguchi

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Background: Vascular endothelial growth factor (VEGF) overexpression has been observed in several malignant tumors, and VEGF level in serum appears to be correlated with tumor burden in cancer patients. Patients and Methods: Serum VEGF levels were measured in 70 patients with lung cancel including 23 with adenocarcinoma, 19 with squamous cell carcinoma, 3 with large cell carcinoma, and 25 with small cell carcinoma, and in 30 patients with benign lung disease and 13 healthy subjects with an enzyme immunonssay. Results: VEGF levels (mean ± SD; pg/ml) were 834 ± 699 and 732 ± 529 in patients with lung cancer and benign lung disease, respectively, and were significantly higher than those in healthy subjects (264 ± 129) (P <0.01). There were no differences between VEGF levels categorized by histology, disease stage, or distant metastasis for lung cancer patients. Conclusions: Although serum VEGF levels were increased in lung cancer patients, this increase might not have been related to tumor burden.

Original languageEnglish
Pages (from-to)1251-1254
Number of pages4
JournalAnticancer Research
Volume18
Issue number2 B
Publication statusPublished - Mar 1998
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor A
Lung Neoplasms
Serum
Tumor Burden
Lung Diseases
Healthy Volunteers
Large Cell Carcinoma
Small Cell Carcinoma
Squamous Cell Carcinoma
Neoplasms
Histology
Adenocarcinoma
Neoplasm Metastasis
Lung
Enzymes

Keywords

  • Lung cancer
  • Tumor marker
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Takigawa, N., Segawa, Y., Fujimoto, N., Hotta, K., & Eguchi, K. (1998). Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. Anticancer Research, 18(2 B), 1251-1254.

Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. / Takigawa, Nagio; Segawa, Yoshihiko; Fujimoto, Nobukazu; Hotta, Katsuyuki; Eguchi, Kenji.

In: Anticancer Research, Vol. 18, No. 2 B, 03.1998, p. 1251-1254.

Research output: Contribution to journalArticle

Takigawa, N, Segawa, Y, Fujimoto, N, Hotta, K & Eguchi, K 1998, 'Elevated vascular endothelial growth factor levels in sera of patients with lung cancer', Anticancer Research, vol. 18, no. 2 B, pp. 1251-1254.
Takigawa, Nagio ; Segawa, Yoshihiko ; Fujimoto, Nobukazu ; Hotta, Katsuyuki ; Eguchi, Kenji. / Elevated vascular endothelial growth factor levels in sera of patients with lung cancer. In: Anticancer Research. 1998 ; Vol. 18, No. 2 B. pp. 1251-1254.
@article{00b9b998cd1b456396c509fd108efdd2,
title = "Elevated vascular endothelial growth factor levels in sera of patients with lung cancer",
abstract = "Background: Vascular endothelial growth factor (VEGF) overexpression has been observed in several malignant tumors, and VEGF level in serum appears to be correlated with tumor burden in cancer patients. Patients and Methods: Serum VEGF levels were measured in 70 patients with lung cancel including 23 with adenocarcinoma, 19 with squamous cell carcinoma, 3 with large cell carcinoma, and 25 with small cell carcinoma, and in 30 patients with benign lung disease and 13 healthy subjects with an enzyme immunonssay. Results: VEGF levels (mean ± SD; pg/ml) were 834 ± 699 and 732 ± 529 in patients with lung cancer and benign lung disease, respectively, and were significantly higher than those in healthy subjects (264 ± 129) (P <0.01). There were no differences between VEGF levels categorized by histology, disease stage, or distant metastasis for lung cancer patients. Conclusions: Although serum VEGF levels were increased in lung cancer patients, this increase might not have been related to tumor burden.",
keywords = "Lung cancer, Tumor marker, Vascular endothelial growth factor",
author = "Nagio Takigawa and Yoshihiko Segawa and Nobukazu Fujimoto and Katsuyuki Hotta and Kenji Eguchi",
year = "1998",
month = "3",
language = "English",
volume = "18",
pages = "1251--1254",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 B",

}

TY - JOUR

T1 - Elevated vascular endothelial growth factor levels in sera of patients with lung cancer

AU - Takigawa, Nagio

AU - Segawa, Yoshihiko

AU - Fujimoto, Nobukazu

AU - Hotta, Katsuyuki

AU - Eguchi, Kenji

PY - 1998/3

Y1 - 1998/3

N2 - Background: Vascular endothelial growth factor (VEGF) overexpression has been observed in several malignant tumors, and VEGF level in serum appears to be correlated with tumor burden in cancer patients. Patients and Methods: Serum VEGF levels were measured in 70 patients with lung cancel including 23 with adenocarcinoma, 19 with squamous cell carcinoma, 3 with large cell carcinoma, and 25 with small cell carcinoma, and in 30 patients with benign lung disease and 13 healthy subjects with an enzyme immunonssay. Results: VEGF levels (mean ± SD; pg/ml) were 834 ± 699 and 732 ± 529 in patients with lung cancer and benign lung disease, respectively, and were significantly higher than those in healthy subjects (264 ± 129) (P <0.01). There were no differences between VEGF levels categorized by histology, disease stage, or distant metastasis for lung cancer patients. Conclusions: Although serum VEGF levels were increased in lung cancer patients, this increase might not have been related to tumor burden.

AB - Background: Vascular endothelial growth factor (VEGF) overexpression has been observed in several malignant tumors, and VEGF level in serum appears to be correlated with tumor burden in cancer patients. Patients and Methods: Serum VEGF levels were measured in 70 patients with lung cancel including 23 with adenocarcinoma, 19 with squamous cell carcinoma, 3 with large cell carcinoma, and 25 with small cell carcinoma, and in 30 patients with benign lung disease and 13 healthy subjects with an enzyme immunonssay. Results: VEGF levels (mean ± SD; pg/ml) were 834 ± 699 and 732 ± 529 in patients with lung cancer and benign lung disease, respectively, and were significantly higher than those in healthy subjects (264 ± 129) (P <0.01). There were no differences between VEGF levels categorized by histology, disease stage, or distant metastasis for lung cancer patients. Conclusions: Although serum VEGF levels were increased in lung cancer patients, this increase might not have been related to tumor burden.

KW - Lung cancer

KW - Tumor marker

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=0031803176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031803176&partnerID=8YFLogxK

M3 - Article

C2 - 9615796

AN - SCOPUS:0031803176

VL - 18

SP - 1251

EP - 1254

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 B

ER -